Priority blood substitute

The blood substitute developed by Kaluga scientists has become a priority project of the Ministry of Defense of the Russian Federation

The drug can be included in the reserves of the state reserve in case of war, terrorist attacks and disasters

Alevtina Zubrilina, TASS

The blood substitute for military medicine, developed by scientists of the Alliance of Competencies "Active Molecules Park" (AK "PAM") of the Kaluga region, was among the projects supported by the Ministry of Defense of the Russian Federation. The drug can enter the reserves of the state reserve in case of war, terrorist attacks and disasters, the press service of the Kaluga government reports today.

"The blood substitute – polyhemoglobin under the conditional name PAM-3, developed by the Alliance of Competencies of AK PAM, was among the projects supported by the Ministry of Defense of the Russian Federation," the message says.

According to the developers, there are no world analogues with the properties of polyhemoglobin. The drug has passed the first stage of human clinical trials. "Subject to the successful completion of the second and third stages, the technology for obtaining polyhemoglobin in the very near future can become a breakthrough not only in the domestic, but also in the foreign markets of blood substitutes," the press service notes.

The government clarifies that studies of the drug can be included in the plan of scientific work under the state defense order. In addition, the drug can enter the reserves of the state reserve of the Ministry of Defense and the Ministry of Emergency Situations in case of war, terrorist attacks and disasters.

Polyhemoglobin provides oxygen transport to tissues and stimulation of hematopoiesis in conditions of insufficient blood supply associated with blood loss or ischemia of organs, serves as a full-fledged replacement of donor red blood cells in urgent and emergency situations. PAM-3 is a long-term storage powder, standard electrolytes can be used for its dilution and intravenous administration. It can be used for acute blood loss in case of a possible combat injury, as well as for the treatment of ischemia of organs and tissues caused by partial blockage of blood vessels supplying them with oxygen.

The developers note that there are no new modern blood substitutes in Russia now, the only known hemoglobin-based drug is Erigem, developed in the USSR in the middle of the last century.

The Alliance of Competencies "PAM" was formed on the basis of the Medbiopharm Group of Companies, which is a resident of Skolkovo. One of the main directions of its activity is the development and introduction of pharmaceutical substances, as well as conducting clinical trials. The residents of PAMA are manufacturing enterprises, research centers working in the field of innovative biopharmaceuticals.

Portal "Eternal youth" http://vechnayamolodost.ru  10.04.2017